Search
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 2 of 2 items.
FASLODEX (fulvestrant) - Risk of Unnecessary Therapy Modification due to Falsely Elevated Estradiol Levels
AlertHealth professional risk communication | 2016-10-18
SGLT2 Inhibitors [INVOKANA (canagliflozin), FORXIGA (dapagliflozin), XIGDUO (dapagliflozin/metformin), JARDIANCE (empagliflozin)] - Risk of Diabetic Ketoacidosis
AlertHealth professional risk communication | 2016-05-16